156 related articles for article (PubMed ID: 36121439)
41. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
Michiels JJ; Smejkal P; Penka M; Batorova A; Pricangova T; Budde U; Vangenechten I; Gadisseur A
Clin Appl Thromb Hemost; 2017 Sep; 23(6):518-531. PubMed ID: 27443694
[TBL] [Abstract][Full Text] [Related]
43. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
Eikenboom JC; Matsushita T; Reitsma PH; Tuley EA; Castaman G; Briët E; Sadler JE
Blood; 1996 Oct; 88(7):2433-41. PubMed ID: 8839833
[TBL] [Abstract][Full Text] [Related]
44. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.
Atiq F; Schütte LM; Looijen AEM; Boender J; Cnossen MH; Eikenboom J; de Maat MPM; Kruip MJHA; Leebeek FWG
Blood Adv; 2019 Dec; 3(24):4147-4154. PubMed ID: 31834934
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease.
Casonato A; Cattini MG; Daidone V; Pontara E; Bertomoro A; Prandoni P
PLoS One; 2016; 11(8):e0161310. PubMed ID: 27532107
[TBL] [Abstract][Full Text] [Related]
46. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
Yadegari H; Driesen J; Pavlova A; Biswas A; Hertfelder HJ; Oldenburg J
Thromb Haemost; 2012 Oct; 108(4):662-71. PubMed ID: 22871923
[TBL] [Abstract][Full Text] [Related]
47. How Do Laboratories Perform von Willebrand Disease Diagnostics and Classification of von Willebrand Disease Patients? Results from External Quality Data and an International Survey.
Hollestelle MJ; Meijers JCM; Meijer P
Semin Thromb Hemost; 2022 Sep; 48(6):739-749. PubMed ID: 36223773
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
[TBL] [Abstract][Full Text] [Related]
49. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease.
Ferrari M; Galvanin F; Barolo M; Daidone V; Padrini R; Bezzo F; Casonato A
Thromb Haemost; 2018 Feb; 118(2):309-319. PubMed ID: 29378356
[TBL] [Abstract][Full Text] [Related]
50. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
51. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
[TBL] [Abstract][Full Text] [Related]
52. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis.
James AH; Konkle BA; Kouides P; Ragni MV; Thames B; Gupta S; Sood S; Fletcher SK; Philipp CS
Haemophilia; 2015 Jan; 21(1):81-7. PubMed ID: 25333737
[TBL] [Abstract][Full Text] [Related]
53. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.
Casonato A; Sartori MT; Pontara E; Zucchetto A; Dannhäuser D; Patrassi G; Girolami A
Blood Coagul Fibrinolysis; 1992 Apr; 3(2):149-53. PubMed ID: 1606286
[TBL] [Abstract][Full Text] [Related]
54. New advances in the diagnosis of von Willebrand disease.
Sharma R; Haberichter SL
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):596-600. PubMed ID: 31808831
[TBL] [Abstract][Full Text] [Related]
55. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
56. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis of inherited von Willebrand disease: a clinical perspective.
Federici AB
Semin Thromb Hemost; 2006 Sep; 32(6):555-65. PubMed ID: 16977566
[TBL] [Abstract][Full Text] [Related]
58. A 12.3-kb Duplication Within the
Lehner S; Ekhlasi-Hundrieser M; Detering C; Allerkamp H; Pfarrer C; von Depka Prondzinski M
G3 (Bethesda); 2018 Feb; 8(2):577-585. PubMed ID: 29208651
[TBL] [Abstract][Full Text] [Related]
59. The Course of von Willebrand Factor and Factor VIII Activity in Patients with von Willebrand Disease during Pregnancy.
Delbrück C; Miesbach W
Acta Haematol; 2019; 142(2):71-78. PubMed ID: 31085919
[TBL] [Abstract][Full Text] [Related]
60. Evaluating Performance of Contemporary and Historical von Willebrand Factor (VWF) Assays in the Laboratory Identification of von Willebrand Disease (VWD): The Australasian Experience.
Favaloro EJ; Dean E; Arunachalam S
Semin Thromb Hemost; 2022 Sep; 48(6):711-731. PubMed ID: 35803263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
